The Risk of Thromboembolism in Users of Antidepressants and Antipsychotics
Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt
Standard
The Risk of Thromboembolism in Users of Antidepressants and Antipsychotics. / Adelborg, Kasper; Sundbøll, Jens; Videbech, Poul; Grove, Erik L.
Thrombosis and Embolism: from Research to Clinical Practice. Bind 906 2017. s. 351-361 (Advances in Experimental Medicine and Biology).Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - CHAP
T1 - The Risk of Thromboembolism in Users of Antidepressants and Antipsychotics
AU - Adelborg, Kasper
AU - Sundbøll, Jens
AU - Videbech, Poul
AU - Grove, Erik L
PY - 2017
Y1 - 2017
N2 - Arterial and venous thromboembolism are common causes of morbidity and mortality in the Western world. Mental disorders are also highly prevalent with a lifetime risk of experiencing any psychiatric disease ranging between 32 % and 37 %. Depression and schizophrenia may increase the risk of thromboembolism through genetic, behavioral, and biological mechanisms. Treatment of psychiatric patients with psychotropic drugs is imperative to improve quality of life and to reduce morbidity and mortality. However, studies have shown that psychotropic drugs themselves may modify the risk of arterial and venous thromboembolism, which should be taken into consideration when using these drugs in clinical practice. This association is, however, multifactorial, complex and susceptible to several confounding factors. Psychotropic drugs are widely prescribed, also among patients with cardiovascular disease. Therefore, understanding the association with thromboembolism and the underlying pathophysiological mechanisms is of major importance and will be reviewed in this chapter.
AB - Arterial and venous thromboembolism are common causes of morbidity and mortality in the Western world. Mental disorders are also highly prevalent with a lifetime risk of experiencing any psychiatric disease ranging between 32 % and 37 %. Depression and schizophrenia may increase the risk of thromboembolism through genetic, behavioral, and biological mechanisms. Treatment of psychiatric patients with psychotropic drugs is imperative to improve quality of life and to reduce morbidity and mortality. However, studies have shown that psychotropic drugs themselves may modify the risk of arterial and venous thromboembolism, which should be taken into consideration when using these drugs in clinical practice. This association is, however, multifactorial, complex and susceptible to several confounding factors. Psychotropic drugs are widely prescribed, also among patients with cardiovascular disease. Therefore, understanding the association with thromboembolism and the underlying pathophysiological mechanisms is of major importance and will be reviewed in this chapter.
KW - Antidepressive Agents/administration & dosage
KW - Antipsychotic Agents/administration & dosage
KW - Depression/drug therapy
KW - Gastrointestinal Hemorrhage/chemically induced
KW - Humans
KW - Quality of Life
KW - Risk Factors
KW - Schizophrenia/drug therapy
KW - Serotonin Uptake Inhibitors/administration & dosage
KW - Thromboembolism/chemically induced
U2 - 10.1007/5584_2016_125
DO - 10.1007/5584_2016_125
M3 - Book chapter
C2 - 27638627
VL - 906
T3 - Advances in Experimental Medicine and Biology
SP - 351
EP - 361
BT - Thrombosis and Embolism: from Research to Clinical Practice
ER -
ID: 197333627